Physician profile
Brian S Cooperman
NPI 1386615813
$1,917.49
in general payments reported to CMS, 2019-2025
24 companies · $14.70 in 2025
The $14.70 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $1,100 · 2021: $111 · 2022: $108 · 2023: $89.23 · 2025: $14.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $900.00 | 2020 | |
| Abbvie INC. | $309.58 | 2019-2023 | Lo Loestrin Fe |
| Amag Pharmaceuticals, INC. | $85.31 | 2019-2020 | |
| Lupin INC. | $76.36 | 2019-2020 | |
| Allergan, INC. | $52.98 | 2019 | |
| Hologic Sales and Service, LLC | $48.67 | 2021-2023 | Aptima, Thinprep 2000 Processor |
| Millicent US INC | $48.17 | 2019-2020 | |
| Pfizer INC. | $39.24 | 2019 | |
| Coopersurgical, INC. | $35.98 | 2019 | |
| Therapeuticsmd, INC. | $32.73 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $29.77 | 2023 | |
| Smith+Nephew, INC. | $28.66 | 2019-2020 | |
| Organon LLC | $27.61 | 2022 | |
| Exeltis, USA INC. | $25.99 | 2019-2020 | |
| Daiichi Sankyo INC. | $22.68 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $19.96 | 2019 | |
| Zimmer Biomet Holdings, INC. | $19.81 | 2019 | |
| Duchesnay USA Incorporated | $19.09 | 2019 | |
| Astellas Pharma US INC | $19.03 | 2023 | Veozah |
| Agile Therapeutics, INC. | $17.76 | 2021 | |
| Mission Pharmacal Company | $16.21 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.52 | 2019 | |
| Biogen, INC. | $14.70 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Cooperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.